Estrella Immunopharma (NASDAQ:ESLA) Shares Down 2% – Should You Sell?

Estrella Immunopharma, Inc. (NASDAQ:ESLA) shares were down 2% during trading on Wednesday . The company traded as low as $0.9501 and last traded at $0.98. 47,381 shares were traded during mid-day trading, an increase of 20% from the average daily volume of 39,393 shares. The stock had previously closed at $1.00.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Price Performance

The business’s fifty day simple moving average is $1.27 and its two-hundred day simple moving average is $1.29. The company has a market cap of $42.17 million, a PE ratio of -2.88 and a beta of 0.85.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. As a group, analysts predict that Estrella Immunopharma, Inc. will post -0.39 EPS for the current year.

Institutional Investors Weigh In On Estrella Immunopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in ESLA. XTX Topco Ltd raised its position in shares of Estrella Immunopharma by 376.9% during the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares during the last quarter. Marshall Wace LLP purchased a new position in Estrella Immunopharma during the fourth quarter worth approximately $88,000. Renaissance Technologies LLC raised its holdings in shares of Estrella Immunopharma by 1,045.7% during the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after acquiring an additional 111,779 shares during the period. Geode Capital Management LLC raised its stake in Estrella Immunopharma by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after purchasing an additional 8,318 shares during the period. Finally, State Street Corp lifted its holdings in Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after acquiring an additional 20,900 shares during the last quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.